{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:17:54Z","timestamp":1793395074904,"version":"4.5.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07308-2","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:46:12Z","timestamp":1765874772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Exploiting artificial intelligence in precision oncology: an updated comprehensive review"],"prefix":"10.1186","volume":"23","author":[{"given":"Roaa Yousry","family":"Goda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-1183","authenticated-orcid":false,"given":"Amal Kamal","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"7308_CR1","first-page":"65","volume":"9","author":"JN Patel","year":"2016","unstructured":"Patel JN. Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives. Pharmgenomics Pers Med. 2016;9:65\u201377.","journal-title":"Pharmgenomics Pers Med"},{"key":"7308_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40364-025-00764-4","volume":"13","author":"V Dewaker","year":"2025","unstructured":"Dewaker V, Morya VK, Kim YH, Park ST, Kim HS, Koh YH. Revolutionizing oncology: the role of artificial intelligence (AI) as an antibody design, and optimization tools. Biomark Res. 2025;13:52.","journal-title":"Biomark Res"},{"key":"7308_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/joim.13709","volume":"294","author":"A Edsj\u00f6","year":"2023","unstructured":"Edsj\u00f6 A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabi\u00e8res C, et al. Precision cancer medicine: concepts, current practice, and future developments. J Intern Med. 2023;294:455\u201381.","journal-title":"J Intern Med"},{"key":"7308_CR4","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani D, Kumar A, Br\u00fcck O, Kontro M, Yadav B, Helles\u00f8y M, et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 2022;12:388\u2013401.","journal-title":"Cancer Discov"},{"key":"7308_CR5","first-page":"49","volume":"2","author":"KA Lipinski","year":"2016","unstructured":"Lipinski KA, Barber LJ, Davies MN, Ashenden M, Sottoriva A, Gerlinger M. Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer. 2016;2:49\u201363.","journal-title":"Cancer Evol And The Limits Of Predictability In Precis Cancer Med Trends In Cancer"},{"key":"7308_CR6","doi-asserted-by":"publisher","first-page":"12613","DOI":"10.3390\/ijms241612613","volume":"24","author":"SL Rulten","year":"2023","unstructured":"Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM. The future of precision oncology. Int J Mol Sci. 2023;24:12613.","journal-title":"Int J Mol Sci"},{"key":"7308_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/PPO.0000000000000386","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, Doroshow JH. From the broad phase II trial to precision oncology: a perspective on the origins of basket and umbrella clinical trial designs in cancer drug development. Cancer J. 2019;25:245\u201353.","journal-title":"Cancer J"},{"key":"7308_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13073-021-00968-x","volume":"13","author":"KA Tran","year":"2021","unstructured":"Tran KA, Kondrashova O, Bradley A, Williams ED, Pearson J V, Waddell N. Deep learning in cancer diagnosis, prognosis and treatment selection. Genome Med. 2021;13:152.","journal-title":"Genome Med"},{"key":"7308_CR9","doi-asserted-by":"crossref","unstructured":"Athanasopoulou K, Michalopoulou S VI, Adamopoulos A, PG. Integrating artificial intelligence in next-generation sequencing: advances, challenges, and future directions. Curr Issues Mol Biol. 2025;47.","DOI":"10.3390\/cimb47060470"},{"key":"7308_CR10","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.csbj.2020.08.019","volume":"18","author":"Z Dlamini","year":"2020","unstructured":"Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. Comput Struct Biotechnol J. 2020;18:2300\u201311.","journal-title":"Comput Struct Biotechnol J"},{"key":"7308_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1139\/gen-2020-0131","volume":"64","author":"SJ MacEachern","year":"2021","unstructured":"MacEachern SJ, Forkert ND. Machine learning for precision medicine. Genome. 2021;64:416\u201325.","journal-title":"Genome"},{"key":"7308_CR12","doi-asserted-by":"publisher","first-page":"110178","DOI":"10.1016\/j.compbiomed.2025.110178","volume":"191","author":"A Vyas","year":"2025","unstructured":"Vyas A, Kumar K, Sharma A, Verma D, Bhatia D, Wahi N, et al. Advancing the frontier of artificial intelligence on emerging technologies to redefine cancer diagnosis and care. Comput Biol Med. 2025;191:110178.","journal-title":"Comput Biol Med"},{"key":"7308_CR13","doi-asserted-by":"crossref","unstructured":"Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers. 2021.","DOI":"10.1007\/s11030-021-10217-3"},{"key":"7308_CR14","first-page":"1","volume":"9","author":"RY Choi","year":"2020","unstructured":"Choi RY, Coyner AS, Kalpathy-Cramer J, Chiang MF, Peter Campbell J. Introduction to machine learning, neural networks, and deep learning. Transl Vis Sci Technol. 2020;9:1\u201312.","journal-title":"Transl Vis Sci Technol"},{"key":"7308_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/bmb\/ldab016","volume":"139","author":"YYM Aung","year":"2021","unstructured":"Aung YYM, Wong DCS, Ting DSW. The promise of artificial intelligence: a review of the opportunities and challenges of artificial intelligence in healthcare. Br Med Bull. 2021;139:4\u201315.","journal-title":"Br Med Bull"},{"key":"7308_CR16","doi-asserted-by":"crossref","unstructured":"Kufel J, Bargie\u0142-\u0141\u0105czek K, Kocot S, Ko\u017alik M, Bartnikowska W, Janik M, et al. What is machine learning, artificial neural networks and deep learning?-examples of practical applications in medicine. Diagnostics. 2023;13.","DOI":"10.3390\/diagnostics13152582"},{"key":"7308_CR17","doi-asserted-by":"crossref","unstructured":"Bhalla S, Lagan\u00e0 A. Artificial intelligence for precision oncology. 2022;249\u201368.","DOI":"10.1007\/978-3-030-91836-1_14"},{"key":"7308_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","volume":"13","author":"W Fiskus","year":"2023","unstructured":"Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, et al. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023;13:53.","journal-title":"Blood Cancer J"},{"key":"7308_CR19","doi-asserted-by":"publisher","first-page":"115709","DOI":"10.1016\/j.bcp.2023.115709","volume":"215","author":"AK Abdel-Aziz","year":"2023","unstructured":"Abdel-Aziz AK. Advances in acute myeloid leukemia differentiation therapy: a critical review. Biochem Pharmacol. 2023;215:115709.","journal-title":"Biochem Pharmacol"},{"key":"7308_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.drup.2009.07.001","volume":"12","author":"HJ Broxterman","year":"2009","unstructured":"Broxterman HJ, Gotink KJ, Verheul HMW. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat. 2009;12:114\u201326.","journal-title":"Drug Resist Updat"},{"key":"7308_CR21","doi-asserted-by":"publisher","first-page":"12404","DOI":"10.18632\/oncotarget.7189","volume":"7","author":"S-G Wu","year":"2016","unstructured":"Wu S-G, Liu Y-N, Tsai M-F, Chang Y-L, Yu C-J, Yang P-C, et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016;7:12404\u201313.","journal-title":"Oncotarget"},{"key":"7308_CR22","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"N Tcgar","year":"2013","unstructured":"Tcgar N. Genomic and epigenomic landscapes of adult De novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"7308_CR23","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/s41375-022-01530-3","volume":"36","author":"S Moretti","year":"2022","unstructured":"Moretti S, Abdel-Aziz AK, Ceccacci E, Pallavicini I, Santoro F, de Th\u00e9 H, et al. Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication. Leukemia. 2022;36:1306\u201312.","journal-title":"Leukemia"},{"key":"7308_CR24","doi-asserted-by":"publisher","first-page":"104139","DOI":"10.1016\/j.critrevonc.2023.104139","volume":"191","author":"AK Abdel-Aziz","year":"2023","unstructured":"Abdel-Aziz AK, Dokla EME, Saadeldin MK. FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: an updated comprehensive review. Crit Rev Oncol Hematol. 2023;191:104139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7308_CR25","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2147\/OTT.S384293","volume":"15","author":"M Tecik","year":"2022","unstructured":"Tecik M, Adan A. Therapeutic targeting of FLT3 in acute myeloid leukemia: current status and novel approaches. Onco Targets Ther. 2022;15:1449\u201378.","journal-title":"Onco Targets Ther"},{"key":"7308_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.anl.2023.08.006","volume":"51","author":"T Kumai","year":"2024","unstructured":"Kumai T, Shinomiya H, Shibata H, Takahashi H, Kishikawa T, Okada R, et al. Translational research in head and neck cancer: molecular and immunological updates. Auris Nasus Larynx. 2024;51:391\u2013400.","journal-title":"Auris Nasus Larynx"},{"key":"7308_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/med.20070","volume":"26","author":"S Kamath","year":"2006","unstructured":"Kamath S, Buolamwini JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev. 2006;26:569\u201394.","journal-title":"Med Res Rev"},{"key":"7308_CR28","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.leukres.2008.04.023","volume":"32","author":"JH Chien","year":"2008","unstructured":"Chien JH, Tang JL, Chen RL, Li CC, Lee CP. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Leuk Res. 2008;32:1724\u201334.","journal-title":"Leuk Res"},{"key":"7308_CR29","doi-asserted-by":"crossref","unstructured":"Abdel-Aziz AK, Azab SSE, Youssef SS, El-Sayed AM, El-Demerdash E, Shouman S. Modulation of imatinib cytotoxicity by selenite in HCT116 colorectal cancer cells. Basic Clin Pharmacol Toxicol. 2015;116.","DOI":"10.1111\/bcpt.12281"},{"key":"7308_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/gtc.12022","volume":"18","author":"D Kitagawa","year":"2013","unstructured":"Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells. 2013;18:110\u201322.","journal-title":"Genes Cells"},{"key":"7308_CR31","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/ijc.28434","volume":"134","author":"J Yang","year":"2014","unstructured":"Yang J, Ikezoe T, Nishioka C, Udaka K, Yokoyama A. Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling. Int J Cance. 2014;134:1183\u201394.","journal-title":"Int. J. Cancer"},{"key":"7308_CR32","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","volume":"19","author":"A Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, M\u00fcller-Br\u00fcsselbach S, et al. Compensatory PI3-kinase\/akt\/mtor activation regulates imatinib resistance development. Leukemia. 2005;19:1774\u201382.","journal-title":"Leukemia"},{"key":"7308_CR33","doi-asserted-by":"publisher","first-page":"116596","DOI":"10.1016\/j.bmc.2021.116596","volume":"56","author":"EME Dokla","year":"2022","unstructured":"Dokla EME, Abdel-Aziz AK, Milik SN, McPhillie MJ, Minucci S, Abouzid KAM. Discovery of a benzimidazole-based dual FLT3\/TrKA inhibitor targeting acute myeloid leukemia. Bioorg Med Chem. 2022;56:116596.","journal-title":"Bioorg Med Chem"},{"key":"7308_CR34","doi-asserted-by":"publisher","first-page":"132724","DOI":"10.1016\/j.molstruc.2022.132724","volume":"1259","author":"SN Milik","year":"2022","unstructured":"Milik SN, Abdel-Aziz AK, El-Hendawy MM, El-Gogary RI, Saadeldin MK, Minucci S, et al. Insights into the design of inhibitors of the EGFR family with anticancer activity overcoming resistance: a case of optimizing thieno[2, 3-d]pyrimidine-based EGFR inhibitors. J Mol Struct. 2022;1259:132724.","journal-title":"J Mol Struct"},{"key":"7308_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ejmech.2018.06.011","volume":"155","author":"SN Milik","year":"2018","unstructured":"Milik SN, Abdel-Aziz AK, Lasheen DS, Serya RAT, Minucci S, Abouzid KAM. Surmounting the resistance against EGFR inhibitors through the development of thieno[2, 3-d]pyrimidine-based dual EGFR\/HER2 inhibitors. Eur J Med Chem. 2018;155:316\u201336.","journal-title":"Eur J Med Chem"},{"key":"7308_CR36","doi-asserted-by":"publisher","first-page":"101490","DOI":"10.1016\/j.rechem.2024.101490","volume":"7","author":"R Mariam Raju","year":"2024","unstructured":"Mariam Raju R, Joy A J, Nulgumnalli Manjunathaiah R, Justin A, Prashantha Kumar BR. EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: a critical review. Results Chem. 2024;7:101490.","journal-title":"Results Chem"},{"key":"7308_CR37","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, a RM, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011\u201319.","journal-title":"Lancet"},{"key":"7308_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.expneurol.2016.06.004","volume":"283","author":"AK Abdel-Aziz","year":"2016","unstructured":"Abdel-Aziz AK, Mantawy EM, Said RS, Helwa R. The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries. Exp Neurol. 2016;283:129\u201341.","journal-title":"Exp Neurol"},{"key":"7308_CR39","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","volume":"39","author":"SK Joshi","year":"2021","unstructured":"Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. 2021;39:999\u20131014.e8.","journal-title":"Cancer Cell"},{"key":"7308_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-023-02005-w","volume":"40","author":"A Khadela","year":"2023","unstructured":"Khadela A, Shah Y, Mistry P, Mansuri M, Sureja D, Bodiwala K. A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. Med Oncol. 2023;40:1\u201313.","journal-title":"Med Oncol"},{"key":"7308_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1172\/JCI84386","volume":"127","author":"M Elgendy","year":"2017","unstructured":"Elgendy M, Abdel-Aziz AK, Renne SL, Bornaghi V, Procopio G, Colecchia M, et al. Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J. Clin. Invest. 2017;127:153\u201368.","journal-title":"J. Clin. Invest"},{"key":"7308_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00718","volume":"8","author":"AK Abdel-Aziz","year":"2017","unstructured":"Abdel-Aziz AK, Abdel-Naim AB, Shouman S, Minucci S. From resistance to sensitivity: insights and implications of biphasic modulation of autophagy by sunitinib. Front Pharmacol. 2017;8:1\u201310.","journal-title":"Front Pharmacol"},{"key":"7308_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7308_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2019.08.013","volume":"122","author":"AK Abdel-Aziz","year":"2019","unstructured":"Abdel-Aziz AK, Saadeldin MK, D\u2019Amico P, Orecchioni S, Bertolini F, Curigliano G, et al. Preclinical models of breast cancer: two-way shuttles for immune checkpoint inhibitors from and to patient bedside. Eur J Cancer. 2019;122:22\u201341.","journal-title":"Eur J Cancer"},{"key":"7308_CR45","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2019","unstructured":"Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase ib KEYNOTE-012 study. J Clin Oncol. 2019;34:2460\u201367.","journal-title":"J Clin Oncol"},{"key":"7308_CR46","doi-asserted-by":"publisher","first-page":"15411","DOI":"10.1007\/s13277-016-5467-2","volume":"37","author":"H Shi","year":"2016","unstructured":"Shi H, Zhang W, Zhi Q, Jiang M. Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms. Tumor Biol. 2016;37:15411\u201331.","journal-title":"Tumor Biol"},{"key":"7308_CR47","doi-asserted-by":"crossref","unstructured":"Hollander N. Immunotherapy for B-cell lymphoma: current status and prospective advances. 2012;3:1\u201315.","DOI":"10.3389\/fimmu.2012.00003"},{"key":"7308_CR48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.21037\/atm.2020.04.07","volume":"8","author":"HS Rehmani","year":"2020","unstructured":"Rehmani HS, Issaeva N. EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations. Ann Transl Med. 2020;8:813\u2013813.","journal-title":"Ann Transl Med"},{"key":"7308_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","volume":"12","author":"K Zhu","year":"2024","unstructured":"Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024;12:16.","journal-title":"Biomark Res"},{"key":"7308_CR50","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1158\/0008-5472.CAN-11-3831","volume":"72","author":"Y-L Hu","year":"2012","unstructured":"Hu Y-L, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012;72:1773\u201383.","journal-title":"Cancer Res"},{"key":"7308_CR51","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1148\/rg.2017170085","volume":"37","author":"GX Wang","year":"2017","unstructured":"Wang GX, Justin F, Sullivan RJ, Flaherty KT, Lee SI. Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics. 2017;37:2132\u201344.","journal-title":"Radiographics"},{"key":"7308_CR52","doi-asserted-by":"crossref","unstructured":"Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. 2017.","DOI":"10.20517\/2394-4722.2017.41"},{"key":"7308_CR53","doi-asserted-by":"crossref","unstructured":"Nixon MJ, Balko JM. Biomarkers for assessing the effectiveness of immunotherapy in breast cancer. 2018;12:97\u2013100.","DOI":"10.2217\/bmm-2017-0408"},{"key":"7308_CR54","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2217\/fon-2020-0967","volume":"17","author":"S Hu-Lieskovan","year":"2021","unstructured":"Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Melissa L. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need. Future Oncol. 2021;17:1401\u201339.","journal-title":"Future Oncol"},{"key":"7308_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118:9\u201316.","journal-title":"Br J Cancer"},{"key":"7308_CR56","doi-asserted-by":"crossref","unstructured":"Lewis GD, Li G, Guo J, Yu SF, Fields CT, Lee G, et al. The HER2-directed antibody-drug conjugate DHES0815A in advanced and\/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nat Commun. 2024;15.","DOI":"10.1038\/s41467-023-44533-z"},{"key":"7308_CR57","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.drudis.2011.06.003","volume":"16","author":"R Zagozdzon","year":"2011","unstructured":"Zagozdzon R, Gallagher WM, Crown J. Truncated HER2: implications for HER2-targeted therapeutics. Drug Discov Today. 2011;16:810\u201316.","journal-title":"Drug Discov Today"},{"key":"7308_CR58","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143\u201354.","journal-title":"N Engl J Med"},{"key":"7308_CR59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/bcp.14407","volume":"87","author":"DF Carr","year":"2021","unstructured":"Carr DF, Turner RM, Pirmohamed M. Pharmacogenomics of anticancer drugs: personalising the choice and dose to manage drug response. Br J Clin Pharmacol. 2021;87:237\u201355.","journal-title":"Br J Clin Pharmacol"},{"key":"7308_CR60","doi-asserted-by":"crossref","unstructured":"Chiranth CR, Kumkum S, Yellapur SG, Desai VP, Reddy AHM, Manokaran S. A review on Pharmacogenomics of anticancer drugs in targeted therapy. Proc Natl Acad Sci, India, Sect B Biol Sci. 2025.","DOI":"10.1007\/s40011-025-01710-y"},{"key":"7308_CR61","doi-asserted-by":"crossref","unstructured":"He Z, Fu X, Xu Z, Alshargi O, Rodr\u00edguez-Labrada R, Zhong X-B. Editorial: pharmacogenomics for improving drug safety and efficacy in cancer. Front Pharmacol. 2025;16.","DOI":"10.3389\/fphar.2025.1649258"},{"key":"7308_CR62","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s40262-022-01174-7","volume":"61","author":"G Narendra","year":"2022","unstructured":"Narendra G, Choudhary S, Raju B, Verma H, Silakari O. Role of genetic polymorphisms in drug-metabolizing enzyme-mediated toxicity and pharmacokinetic resistance to anti-cancer agents: a review on the pharmacogenomics aspect. Clin Pharmacokinet. 2022;61:1495\u2013517.","journal-title":"Clin Pharmacokinet"},{"key":"7308_CR63","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1007\/s00277-023-05364-6","volume":"103","author":"MB Hammami","year":"2024","unstructured":"Hammami MB, Qasim A, Thakur R, Vegivinti CTR, Patton CD, Vikash S, et al. Rasburicase-induced hemolytic anemia and methemoglobinemia: a systematic review of current reports. Ann Hematol. 2024;103:3399\u2013411.","journal-title":"Ann Hematol"},{"key":"7308_CR64","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bcr-2022-252180","volume":"15","author":"I Boussaid","year":"2022","unstructured":"Boussaid I, Mondesir J, Chapuis N, Birsen R. Methaemoglobinaemia and haemolysis after rasburicase administration in a patient with G6PD deficiency. BMJ Case Rep. 2022;15:2\u20133.","journal-title":"BMJ Case Rep"},{"key":"7308_CR65","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"V Relling M","year":"2019","unstructured":"Relling M V, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105:1095\u2013105.","journal-title":"Clin Pharmacol Ther"},{"key":"7308_CR66","first-page":"11","volume":"45","author":"L Ramudo-Cela","year":"2021","unstructured":"Ramudo-Cela L, Busto-Fern\u00e1ndez F, Outeda-Mac\u00edas M, Antol\u00edn S, Calvo-Mart\u00ednez L, Mart\u00edn-Herranz I. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining Clin And Res Approaches Farm Hosp. 2021;45:11\u201337.","journal-title":"Combining Clin And Res Approaches Farm Hosp"},{"key":"7308_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2016.00075","volume":"7","author":"V Bianchi","year":"2016","unstructured":"Bianchi V, Ceol A, Ogier AGE, De Pretis S, Galeota E, Kishore K, et al. Integrated systems for NGS data management and analysis: open issues and available solutions. Front Genet. 2016;7:1\u20138.","journal-title":"Front Genet"},{"key":"7308_CR68","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/bjh.16360","volume":"188","author":"T Haferlach","year":"2020","unstructured":"Haferlach T, Schmidts I. The power and potential of integrated diagnostics in acute myeloid leukaemia. Br J Haematol. 2020;188:36\u201348.","journal-title":"Br J Haematol"},{"key":"7308_CR69","doi-asserted-by":"crossref","unstructured":"Aldea M, Ghigna MR, Lacroix-Triki M, Andre F. Unlocking the potential of AI-assisted pathology for molecular alteration screening. Eur J Cancer Engl. 2024;113467.","DOI":"10.1016\/j.ejca.2023.113467"},{"key":"7308_CR70","doi-asserted-by":"crossref","unstructured":"Wiest IC, Bhat M, Clusmann J, Schneider C V, Jiang X, Kather JN. Large language models for clinical decision support in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol. 2025.","DOI":"10.1038\/s41575-025-01108-1"},{"key":"7308_CR71","doi-asserted-by":"publisher","first-page":"312","DOI":"10.21323\/2618-9771-2024-7-2-312-320","volume":"7","author":"MRT Alifiansyah","year":"2024","unstructured":"Alifiansyah MRT, Herdiansyah MA, Pratiwi RC, Pramesti RP, Hafsyah NW, Rania AP, et al. Qsar of acyl alizarin red Biocompound derivatives of Rubia Tinctorum Roots and its admet properties as anti-breast cancer candidates against mmp-9 protein receptor: in Silico study. Food Syst. 2024;7:312\u201320.","journal-title":"Food Syst"},{"key":"7308_CR72","doi-asserted-by":"publisher","first-page":"384","DOI":"10.15294\/biosaintifika.v16i3.3685","volume":"16","author":"AA Parikesit","year":"2024","unstructured":"Parikesit AA, Ansori ANM, Kharisma VD. Computational design of siRNA targeting homo sapiens HER2 splice variant mRNA: a potential strategy for breast cancer intervention. Biosaintifika. 2024;16:384\u201393.","journal-title":"Biosaintifika"},{"key":"7308_CR73","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.22146\/ijc.68415","volume":"22","author":"AA Parikesit","year":"2022","unstructured":"Parikesit AA, Ansori ANM, Kharisma VD. A computational design of siRNA in SARS-CoV-2 Spike Glycoprotein Gene and its binding capability toward mRNA. Indones J Chem. 2022;22:1163\u201376.","journal-title":"Indones J Chem"},{"key":"7308_CR74","doi-asserted-by":"publisher","first-page":"484","DOI":"10.56499\/jppres21.1047_9.4.484","volume":"9","author":"MH Widyananda","year":"2021","unstructured":"Widyananda MH, Pratama SK, Samoedra RS, Sari FN, Kharisma VD, Ansori ANM, et al. Molecular docking study of sea urchin (Arbacia lixula) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins. J Pharm Pharmacogn Res. 2021;9:484\u201396.","journal-title":"J Pharm Pharmacogn Res"},{"key":"7308_CR75","doi-asserted-by":"crossref","unstructured":"Johnson SJS. AI revolutionizing cell and genetic engineering: innovations and applications. 2025;219\u201332.","DOI":"10.1007\/978-1-0716-4690-8_12"},{"key":"7308_CR76","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.tips.2022.12.005","volume":"44","author":"J Kim","year":"2023","unstructured":"Kim J, McFee M, Fang Q, Abdin O, Kim PM. Computational and artificial intelligence-based methods for antibody development. Trends Pharmacol Sci. 2023;44:175\u201389.","journal-title":"Trends Pharmacol Sci"},{"key":"7308_CR77","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583\u201389.","journal-title":"Nature"},{"key":"7308_CR78","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173:371\u201385.e18.","journal-title":"Cell"},{"key":"7308_CR79","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1021\/acs.jcim.3c01619","volume":"64","author":"P Kamya","year":"2024","unstructured":"Kamya P, Ozerov I V, Pun FW, Tretina K, Fokina T, Chen S, et al. PandaOmics: an AI-Driven platform for therapeutic target and biomarker discovery. J Chem Inf Model. 2024;64:3961\u201369.","journal-title":"J Chem Inf Model"},{"key":"7308_CR80","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.3390\/ijms26104697","volume":"26","author":"D-S Chung","year":"2025","unstructured":"Chung D-S, Leung GHD, Liu S, Lok SWY, Xin Y, Xia Y, et al. AI-Driven drug target screening platform identified oncogene CACNA2D1 activated by enhancer infestation in epstein-barr virus-associated nasopharyngeal carcinoma. Int J Mol Sci. 2025;26:4697.","journal-title":"Int J Mol Sci"},{"key":"7308_CR81","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/17460441.2021.1979514","volume":"17","author":"JI Di Filippo","year":"2022","unstructured":"Di Filippo JI, Cavasotto CN. Guided structure-based ligand identification and design via artificial intelligence modeling. Expert Opin Drug Discov. 2022;17:71\u201378.","journal-title":"Expert Opin Drug Discov"},{"key":"7308_CR82","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1021\/acs.jcim.3c01979","volume":"64","author":"K Yang","year":"2024","unstructured":"Yang K, Xie Z, Li Z, Qian X, Sun N, He T, et al. MolProphet: a one-stop, general purpose, and AI-based platform for the early stages of drug discovery. J Chem Inf Model. 2024;64:2941\u201347.","journal-title":"J Chem Inf Model"},{"key":"7308_CR83","doi-asserted-by":"publisher","first-page":"110209","DOI":"10.1016\/j.abb.2024.110209","volume":"762","author":"AK Pandey","year":"2024","unstructured":"Pandey AK. AI-assisted generation and in-depth in-silico evaluation of potential inhibitor targeting aurora kinase a (AURKA): an anticancer discovery exploiting synthetic lethality approach. Arch Biochem Biophys. 2024;762:110209.","journal-title":"Arch Biochem Biophys"},{"key":"7308_CR84","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/futurepharmacol4030026","volume":"4","author":"MK Saadeldin","year":"2024","unstructured":"Saadeldin MK, Curigliano G, Abdel-Aziz AK. Deciphering the complex interplay of long noncoding RNAs and Aurora Kinases: novel insights into breast cancer development and therapeutic strategies. Futur Pharmacol. 2024;4:466\u201378.","journal-title":"Futur Pharmacol"},{"key":"7308_CR85","doi-asserted-by":"publisher","first-page":"105451","DOI":"10.1016\/j.bioorg.2021.105451","volume":"117","author":"EME Dokla","year":"2021","unstructured":"Dokla EME, Abdel-Aziz AK, Milik SN, Mahmoud AH, Kamal M, Mcphillie MJ, et al. Indolin-2-one derivatives as selective aurora B kinase inhibitors targeting breast cancer. Bioorg Chem. 2021;117:105451.","journal-title":"Bioorg Chem"},{"key":"7308_CR86","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/17460441.2024.2376643","volume":"19","author":"L Manen-Freixa","year":"2024","unstructured":"Manen-Freixa L, Antolin AA. Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery. Expert Opin Drug Discov. 2024;19:1043\u201369.","journal-title":"Expert Opin Drug Discov"},{"key":"7308_CR87","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1158\/2643-3230.BCD-23-0240","volume":"6","author":"F Luciani","year":"2025","unstructured":"Luciani F, Safavi A, Guruprasad P, Chen L, Ruella M. Advancing CAR T-cell therapies with artificial intelligence: opportunities and challenges. Blood Cancer Discov. 2025;6:159\u201362.","journal-title":"Blood Cancer Discov"},{"key":"7308_CR88","doi-asserted-by":"crossref","unstructured":"Li P, Jiang Z, Liu T, Liu X, Qiao H, Yao X. Improving drug response prediction via integrating gene relationships with deep learning. Brief Bioinform. 2024;25.","DOI":"10.1093\/bib\/bbae153"},{"key":"7308_CR89","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1093\/bioinformatics\/btac177","volume":"38","author":"A Park","year":"2022","unstructured":"Park A, Joo M, Kim K, Son W-J, Lim G, Lee J, et al. A comprehensive evaluation of regression-based drug responsiveness prediction models, using cell viability inhibitory concentrations (IC50 values). Bioinformatics. 2022;38:2810\u201317.","journal-title":"Bioinformatics"},{"key":"7308_CR90","doi-asserted-by":"publisher","first-page":"107746","DOI":"10.1016\/j.compbiomed.2023.107746","volume":"168","author":"Y Wang","year":"2024","unstructured":"Wang Y, Yu X, Gu Y, Li W, Zhu K, Chen L, et al. XGraphCDS: an explainable deep learning model for predicting drug sensitivity from gene pathways and chemical structures. Comput Biol Med. 2024;168:107746.","journal-title":"Comput Biol Med"},{"key":"7308_CR91","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12859-024-05669-x","volume":"25","author":"W Pang","year":"2024","unstructured":"Pang W, Chen M, Qin Y. Prediction of anticancer drug sensitivity using an interpretable model guided by deep learning. BMC Bioinf. 2024;25:182.","journal-title":"BMC Bioinf"},{"key":"7308_CR92","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:955\u201361.","journal-title":"Nucleic Acids Res"},{"key":"7308_CR93","doi-asserted-by":"crossref","unstructured":"Tom Hu Z, Yu Y, Chen R, S-J Y, Chen B, Huang H. Large-scale information retrieval and correction of noisy pharmacogenomic datasets through residual thresholded deep matrix factorization. Brief Bioinform. 2025;26.","DOI":"10.1093\/bib\/bbaf226"},{"key":"7308_CR94","first-page":"1","volume":"8","author":"Y Chang","year":"2018","unstructured":"Chang Y, Park H, Yang HJ, Lee S, Lee KY, Kim TS, et al. Cancer drug response profile scan (CDRscan): a deep learning model that predicts drug effectiveness from cancer genomic signature. Sci Rep. 2018;8:1\u201311.","journal-title":"Sci Rep"},{"key":"7308_CR95","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12920-019-0569-5","volume":"12","author":"Y-C Chiu","year":"2019","unstructured":"Chiu Y-C, Chen H-I, Zhang T, Zhang S, Gorthi A, Wang L-J, et al. Correction to: predicting drug response of tumors from integrated genomic profiles by deep neural networks. BMC Med Genomics. 2019;12:119.","journal-title":"BMC Med Genomics"},{"key":"7308_CR96","doi-asserted-by":"publisher","first-page":"11911","DOI":"10.1038\/s41598-023-39179-2","volume":"13","author":"A Park","year":"2023","unstructured":"Park A, Lee Y, Nam S. A performance evaluation of drug response prediction models for individual drugs. Sci Rep. 2023;13:11911.","journal-title":"Sci Rep"},{"key":"7308_CR97","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","volume":"38","author":"B Kuenzi","year":"2020","unstructured":"Kuenzi B, Park J, Fong S, Sanchez K, Lee J, Kreisberg J, et al. Predicting drug response and synergy using a deep learning model of human cancer cells. Cancer Cell. 2020;38:672\u201384.","journal-title":"Cancer Cell"},{"key":"7308_CR98","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/bjh.18193","volume":"198","author":"L Ad\u00e8s","year":"2022","unstructured":"Ad\u00e8s L, Duployez N, Guerci-Bresler A, Laribi K, Peterlin P, Vey N, et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS or low blast AML: GFM\u2019s \u201cpick a winner\u201d trial, with the impact of somatic mutations. Br J Haematol. 2022;198:535\u201344.","journal-title":"Br J Haematol"},{"key":"7308_CR99","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/16078454.2019.1631425","volume":"24","author":"C Kunacheewa","year":"2019","unstructured":"Kunacheewa C, Thongthang P, Ungprasert P, Utchariyaprasit E, Owattanapanich W. A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia. Hematology. 2019;24:498\u2013506.","journal-title":"Hematology"},{"key":"7308_CR100","doi-asserted-by":"crossref","unstructured":"Abdel-Aziz AK, Minucci S. Comparing apples with oranges: studying LSD1 inhibitors in cellular assays. Pharmacol Res. 2019;104345.","DOI":"10.1016\/j.phrs.2019.104345"},{"key":"7308_CR101","doi-asserted-by":"publisher","first-page":"102053","DOI":"10.1016\/j.xcrm.2025.102053","volume":"6","author":"S Chia","year":"2025","unstructured":"Chia S, Wen Seow JJ, Peres da Silva R, Suphavilai C, Shirgaonkar N, Murata-Hori M, et al. CAN-Scan: a multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. Cell Rep Med. 2025;6:102053.","journal-title":"Cell Rep Med"},{"key":"7308_CR102","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf RM. Biomarker definitions and their applications. Exp Biol Med. 2018;243:213\u201321.","journal-title":"Exp Biol Med"},{"key":"7308_CR103","doi-asserted-by":"crossref","unstructured":"Abdel-Aziz AK. OXPHOS mediators in acute myeloid leukemia patients: prognostic biomarkers and therapeutic targets for personalized medicine. World J Surg Oncol. 2024;22.","DOI":"10.1186\/s12957-024-03581-5"},{"key":"7308_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2024.116255","volume":"268","author":"SWA Helmy","year":"2024","unstructured":"Helmy SWA, Abdel-Aziz AK, Dokla EME, Ahmed TE, Hatem Y, Abdel Rahman EA, et al. Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells. Eur J Med Chem. 2024;268:1\u201318.","journal-title":"Eur J Med Chem"},{"key":"7308_CR105","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.ro.2023.02.002","volume":"58","author":"AG Haneberg","year":"2023","unstructured":"Haneberg AG, Pierre K, Winter-Reinhold E, Hochhegger B, Peters KR, Grajo J, et al. Introduction to radiomics and artificial intelligence: a primer for radiologists. Semin Roentgenol. 2023;58:152\u201357.","journal-title":"Semin Roentgenol"},{"key":"7308_CR106","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/ijgc-2024-005580","volume":"34","author":"H Zhou","year":"2024","unstructured":"Zhou H, Zhao Q, Xie Q, Peng Y, Chen M, Huang Z, et al. Preoperative prediction model of lymph node metastasis in the inguinal and femoral region based on radiomics and artificial intelligence. Int J Gynecol Cancer. 2024;34:1437\u201344.","journal-title":"Int J Gynecol Cancer"},{"key":"7308_CR107","doi-asserted-by":"crossref","unstructured":"Zhou L, Ouyang L, Guo B, Huang X, Yang S, Pan J, et al. Enhanced prediction of preoperative mesenteric lymph node metastasis in colorectal cancer using machine learning with CT-based data. MedComm - Futur Med. 2024;3.","DOI":"10.1002\/mef2.100"},{"key":"7308_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3802\/jgo.2024.35.e17","volume":"35","author":"K Monthatip","year":"2024","unstructured":"Monthatip K, Boonnag C, Muangmool T, Charoenkwan K. A machine learning-based prediction model of pelvic lymph node metastasis in women with early-stage cervical cancer. J Gynecol Oncol. 2024;35:1\u201312.","journal-title":"J Gynecol Oncol"},{"key":"7308_CR109","doi-asserted-by":"crossref","unstructured":"Cepeda S, Luppino LT, P\u00e9rez-N\u00fa\u00f1ez A, Solheim O, Garc\u00eda-Garc\u00eda S, Velasco-Casares M, et al. Predicting regions of local recurrence in glioblastomas using voxel-based radiomic features of multiparametric postoperative MRI. Cancers (basel). 2023;15.","DOI":"10.3390\/cancers15061894"},{"key":"7308_CR110","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1186\/s12885-024-13190-w","volume":"24","author":"J Koyama","year":"2024","unstructured":"Koyama J, Morise M, Furukawa T, Oyama S, Matsuzawa R, Tanaka I, et al. Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer. BMC Cancer. 2024;24:1417.","journal-title":"BMC Cancer"},{"key":"7308_CR111","doi-asserted-by":"publisher","first-page":"101743","DOI":"10.1016\/j.cpsurg.2025.101743","volume":"66","author":"F Al-Obeidat","year":"2025","unstructured":"Al-Obeidat F, Rashid A, Hafez W, Gibbaoui H, Ayoub G, Al Ameer S, et al. The accuracy of artificial intelligence in the diagnosis of soft tissue sarcoma: a systematic review and meta-analysis. Curr Probl Surg. 2025;66:101743.","journal-title":"Curr Probl Surg"},{"key":"7308_CR112","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/jmri.28332","volume":"57","author":"H Kang","year":"2023","unstructured":"Kang H, Witanto JN, Pratama K, Lee D, Choi KS, Choi SH, et al. Fully automated MRI segmentation and volumetric measurement of intracranial meningioma using deep learning. J Magn Reson Imag. 2023;57:871\u201381.","journal-title":"J Magn Reson Imag"},{"key":"7308_CR113","doi-asserted-by":"publisher","first-page":"108593","DOI":"10.1016\/j.compbiomed.2024.108593","volume":"177","author":"W Xin","year":"2024","unstructured":"Xin W, Rixin S, Linrui L, Zhihui Q, Long L, Yu Z. Machine learning-based radiomics for predicting outcomes in cervical cancer patients undergoing concurrent chemoradiotherapy. Comput Biol Med. 2024;177:108593.","journal-title":"Comput Biol Med"},{"key":"7308_CR114","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41698-024-00534-9","volume":"8","author":"M Ligero","year":"2024","unstructured":"Ligero M, Gielen B, Navarro V, Cresta Morgado P, Prior O, Dienstmann R, et al. A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking? Npj Precis Oncol. 2024;8:42.","journal-title":"Npj Precis Oncol"},{"key":"7308_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejso.2025.110352","volume":"51","author":"P Tian","year":"2025","unstructured":"Tian P, Chen Z, Fang B, Wang X, Yu X, Lu M. Investigating the relationship between tongue diagnosis features and gastric cancer: a machine learning-based prediction model. Eur J Surg Oncol. 2025;51:1\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"7308_CR116","doi-asserted-by":"publisher","first-page":"eadk 5395","DOI":"10.1126\/scitranslmed.adk5395","volume":"16","author":"S-W Li","year":"2024","unstructured":"Li S-W, Zhang L-H, Cai Y, Zhou X-B, Fu X-Y, Song Y-Q, et al. Deep learning assists detection of esophageal cancer and precursor lesions in a prospective, randomized controlled study. Sci Transl Med. 2024;16:eadk 5395.","journal-title":"Sci Transl Med"},{"key":"7308_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-024-01372-6","volume":"8","author":"H Chen","year":"2025","unstructured":"Chen H, Gou L, Fang Z, Dou Q, Chen H, Chen C, et al. Artificial intelligence assisted real-time recognition of intra-abdominal metastasis during laparoscopic gastric cancer surgery. NPJ Digit Med. 2025;8:1\u201312.","journal-title":"NPJ Digit Med"},{"key":"7308_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200003","volume":"1","author":"I Barua","year":"2022","unstructured":"Barua I, Wieszczy P, Kudo S, Misawa M, Holme \u00d8, Gulati S, et al. Real-time artificial intelligence-based optical diagnosis of neoplastic polyps during colonoscopy. NEJM Evid. 2022;1:1\u201310.","journal-title":"NEJM Evid"},{"key":"7308_CR119","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bju.15382","volume":"129","author":"T Lebret","year":"2022","unstructured":"Lebret T, Pignot G, Colombel M, Guy L, Rebillard X, Savareux L, et al. Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test. BJU Int. 2022;129:356\u201363.","journal-title":"BJU Int"},{"key":"7308_CR120","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00345-023-04519-4","volume":"41","author":"T Lebret","year":"2023","unstructured":"Lebret T, Paoletti X, Pignot G, Roumigui\u00e9 M, Colombel M, Savareux L, et al. Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial. World J Urol. 2023;41:2381\u201388.","journal-title":"World J Urol"},{"key":"7308_CR121","doi-asserted-by":"publisher","first-page":"e17298","DOI":"10.1016\/j.heliyon.2023.e17298","volume":"9","author":"J Aljabban","year":"2023","unstructured":"Aljabban J, Syed S, Syed S, Rohr M, Mukhtar M, Aljabban H, et al. Characterization of monoclonal gammopathy of undetermined significance progression to multiple myeloma through meta-analysis of GEO data. Heliyon. 2023;9:e17298.","journal-title":"Heliyon"},{"key":"7308_CR122","doi-asserted-by":"publisher","first-page":"110619","DOI":"10.1016\/j.compbiomed.2025.110619","volume":"196","author":"V Ruhela","year":"2025","unstructured":"Ruhela V, Gupta R, Oberoi R, Gupta A. A comprehensive targeted panel of 295 genes: unveiling key disease initiating and transformative biomarkers in multiple myeloma. Comput Biol Med. 2025;196:110619.","journal-title":"Comput Biol Med"},{"key":"7308_CR123","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s10495-024-01981-2","volume":"29","author":"Y Hou","year":"2024","unstructured":"Hou Y, Zhang F, Zong J, Li T, Gan W, Lv S, et al. Integrated analysis reveals a novel 5-fluorouracil resistance-based prognostic signature with promising implications for predicting the efficacy of chemotherapy and immunotherapy in patients with colorectal cancer. Apoptosis. 2024;29:1126\u201344.","journal-title":"Apoptosis"},{"key":"7308_CR124","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s41591-019-0462-y","volume":"25","author":"JN Kather","year":"2019","unstructured":"Kather JN, Pearson AT, Halama N, J\u00e4ger D, Krause J, Loosen SH, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019;25:1054\u201356.","journal-title":"Nat Med"},{"key":"7308_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002730","volume":"16","author":"JN Kather","year":"2019","unstructured":"Kather JN, Krisam J, Charoentong P, Luedde T, Herpel E, Weis CA, et al. Predicting survival from colorectal cancer histology slides using deep learning: a retrospective multicenter study. PLoS Med. 2019;16:1\u201322.","journal-title":"PLoS Med"},{"key":"7308_CR126","doi-asserted-by":"crossref","unstructured":"Loeffler CML, Bando H, Sainath S, Muti HS, Jiang X, van Treeck M, et al. HIBRID: histology-based risk-stratification with deep learning and ctDNA in colorectal cancer. Nat Commun. 2025;16.","DOI":"10.1038\/s41467-025-62910-8"},{"key":"7308_CR127","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.eururo.2005.04.015","volume":"48","author":"AW Roddam","year":"2005","unstructured":"Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2\u201310 ng\/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386\u201389.","journal-title":"Eur Urol"},{"key":"7308_CR128","doi-asserted-by":"crossref","unstructured":"Shu CP, Sop TGT, Tanyi TJ, Lambi SJ, Signang NA, Juma PI. The sensitivity and specificity of total prostate specific antigen in the diagnosis of prostate cancer in a resource-limited African setting: a 5-year review in a Kenyan hospital. Clin Genitourin Cancer. 2025;23.","DOI":"10.1016\/j.clgc.2025.102363"},{"key":"7308_CR129","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-25-0269","volume":"85","author":"M Smelik","year":"2025","unstructured":"Smelik M, Diaz-Roncero Gonzalez D, An X, Heer R, Henningsohn L, Li X, et al. Combining spatial transcriptomics, pseudotime, and machine learning enables discovery of biomarkers for prostate cancer. Cancer Res. 2025;85:2514\u201326.","journal-title":"Cancer Res"},{"key":"7308_CR130","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1634\/theoncologist.2018-0255","volume":"24","author":"N Zhou","year":"2019","unstructured":"Zhou N, Zhang C-T, Lv H-Y, Hao C-X, Li T-J, Zhu J-J, et al. Concordance study between IBM Watson for oncology and clinical practice for patients with cancer in China. Oncologist. 2019;24:812\u201319.","journal-title":"Oncologist"},{"key":"7308_CR131","doi-asserted-by":"publisher","first-page":"107329","DOI":"10.1016\/j.compbiomed.2023.107329","volume":"165","author":"S Jamrat","year":"2023","unstructured":"Jamrat S, Sukasem C, Sratthaphut L, Hongkaew Y, Samanchuen T. A precision medicine approach to personalized prescribing using genetic and nongenetic factors for clinical decision-making. Comput Biol Med. 2023;165:107329.","journal-title":"Comput Biol Med"},{"key":"7308_CR132","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1111\/jdv.20286","volume":"38","author":"A Paganelli","year":"2024","unstructured":"Paganelli A, Spadafora M, Navarrete-Dechent C, Guida S, Pellacani G, Longo C. Natural language processing in dermatology: a systematic literature review and state of the art. J Eur Acad Dermatol Venereol. 2024;38:2225\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"7308_CR133","doi-asserted-by":"publisher","unstructured":"Linna N, Kahn CE. Applications of natural language processing in radiology: a systematic review. Int J Med Inf [Internet]. 2022;163:104779. Available from: https:\/\/doi.org\/10.1016\/j.ijmedinf.2022.104779","DOI":"10.1016\/j.ijmedinf.2022.104779"},{"key":"7308_CR134","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/2159-8290.CD-21-0832","volume":"12","author":"X Li","year":"2022","unstructured":"Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, et al. Precision combination therapies based on recurrent oncogenic Coalterations. Cancer Discov. 2022;12:1542\u201359.","journal-title":"Cancer Discov"},{"key":"7308_CR135","first-page":"1","volume":"14","author":"T Ammo","year":"2024","unstructured":"Ammo T, Guillaume VGJ, Hofmann UK, Ulmer NM, Buenting N, Laenger F, et al. Evaluating ChatGPT-4o as a decision support tool in multidisciplinary sarcoma tumor boards: heterogeneous performance across various specialties. Front Oncol. 2024;14:1\u201310.","journal-title":"Front Oncol"},{"key":"7308_CR136","doi-asserted-by":"publisher","first-page":"115408","DOI":"10.1016\/j.ejca.2025.115408","volume":"221","author":"O Akdogan","year":"2025","unstructured":"Akdogan O, Uyar GC, Yesilbas E, Baskurt K, Malkoc NA, Ozdemir N, et al. Effect of a ChatGPT-based digital counseling intervention on anxiety and depression in patients with cancer: a prospective, randomized trial. Eur J Cancer. 2025;221:115408.","journal-title":"Eur J Cancer"},{"key":"7308_CR137","doi-asserted-by":"publisher","first-page":"5990","DOI":"10.1245\/s10434-023-13888-4","volume":"30","author":"Z Al-Hilli","year":"2023","unstructured":"Al-Hilli Z, Noss R, Dickard J, Wei W, Chichura A, Wu V, et al. A randomized trial comparing the effectiveness of pre-test genetic counseling using an artificial intelligence automated Chatbot and traditional In-person genetic counseling in women newly diagnosed with breast cancer. Ann Surg Oncol. 2023;30:5990\u201396.","journal-title":"Ann Surg Oncol"},{"key":"7308_CR138","first-page":"41","volume-title":"Bioinformatics","author":"E-W Yang","year":"2025","unstructured":"Yang E-W, Velazquez-Villarreal E. AI-HOPE: an AI-driven conversational agent for enhanced clinical and genomic data integration in precision medicine research. In: Nikolski M, editor. Bioinformatics. 2025. p. 41."},{"key":"7308_CR139","doi-asserted-by":"crossref","unstructured":"Abdelhalim H, Berber A, Lodi M, Jain R, Nair A, Pappu A, et al. Artificial intelligence, healthcare, clinical genomics, and pharmacogenomics approaches in precision medicine. Front Genet. 2022;13.","DOI":"10.3389\/fgene.2022.929736"},{"key":"7308_CR140","doi-asserted-by":"crossref","unstructured":"Sebastian AM, Peter D. Artificial intelligence in cancer research: trends, challenges and future directions. Life. 2022;12.","DOI":"10.3390\/life12121991"},{"key":"7308_CR141","doi-asserted-by":"crossref","unstructured":"Mehraeen E, Siami H, Montazeryan S, Molavi R, Feyzabadi A, Parvizy I, et al. Artificial intelligence challenges in the healthcare industry: a systematic review of recent evidence. Healthc Technol Lett. 2025;12.","DOI":"10.1049\/htl2.70017"},{"key":"7308_CR142","doi-asserted-by":"crossref","unstructured":"Kore A, Abbasi Bavil E, Subasri V, Abdalla M, Fine B, Dolatabadi E, et al. Empirical data drift detection experiments on real-world medical imaging data. Nat Commun. 2024;15.","DOI":"10.1038\/s41467-024-46142-w"},{"key":"7308_CR143","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11912-024-01627-1","volume":"27","author":"I Dankwa-Mullan","year":"2025","unstructured":"Dankwa-Mullan I, Ndoh K, Akogo D, Rocha HAL, Jua\u00e7aba SF. Artificial intelligence and cancer health equity: bridging the divide or widening the gap. Curr Oncol Rep. 2025;27:95\u2013111.","journal-title":"Curr Oncol Rep"},{"key":"7308_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1057\/s41599-024-03947-w","volume":"11","author":"MS Khan","year":"2024","unstructured":"Khan MS, Umer H, Faruqe F. Artificial intelligence for low income countries. Humanit Soc Sci Commun. 2024;11:1\u201313.","journal-title":"Humanit Soc Sci Commun"},{"key":"7308_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-024-05005-y","volume":"28","author":"G Abgrall","year":"2024","unstructured":"Abgrall G, Holder AL, Chelly Dagdia Z, Zeitouni K, Monnet X. Should AI models be explainable to clinicians? Crit Care. 2024;28:1\u20138.","journal-title":"Crit Care"},{"key":"7308_CR146","doi-asserted-by":"crossref","unstructured":"Xu C, Coen-Pirani P, Jiang X. Empirical study of overfitting in deep learning for predicting breast cancer metastasis. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15071969"},{"key":"7308_CR147","unstructured":"World Health Organization. Ethics and Governance of Artificial Intelligence for Health. Guidance. 2024."},{"key":"7308_CR148","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jama.2024.21451","volume":"333","author":"HJ Warraich","year":"2025","unstructured":"Warraich HJ, Tazbaz T, Califf RM. FDA perspective on the regulation of artificial intelligence in health care and biomedicine. JAMA. 2025;333:241\u201347.","journal-title":"JAMA"},{"key":"7308_CR149","unstructured":"Food and Drug Administration. Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products. 2025. https:\/\/www.fda.gov\/media\/184830\/download, 1\u201323. Available from."},{"key":"7308_CR150","unstructured":"UK Department of Health and Social Care. A guide to good practice for digital and data-driven health technologiesgovernment\/publications\/code-of-conduct-for-data-driven-health-and-care-technology\/initial-code-of-conduct-for-data-driven-health-and-care-technology [Internet]. 2021. https:\/\/www.gov.uk\/government\/publications\/code-of-conduct-for-data-. cited 2025 Sep 21]. p. 1\u201326. Available from."},{"key":"7308_CR151","doi-asserted-by":"publisher","first-page":"105967","DOI":"10.1016\/j.tiv.2024.105967","volume":"102","author":"M Sharaky","year":"2025","unstructured":"Sharaky M, Dokla EME, Abdel-Aziz AK. Anticancer activity of EMD37 against human head and neck cancer: impact on apoptotic and inflammatory machineries. Toxicol Vitr. 2025;102:105967.","journal-title":"Toxicol Vitr"},{"key":"7308_CR152","doi-asserted-by":"crossref","unstructured":"Abdel-Aziz AK, Dokla EME, Abouzid KAM, Minucci S. Discovery of EMD37, a 1, 2, 4-oxadiazole derivative, as a novel endoplasmic reticulum stress inducer with potent anticancer activity. Biochem Pharmacol. 2022;115316.","DOI":"10.1016\/j.bcp.2022.115316"},{"key":"7308_CR153","unstructured":"Id NAP, Xia Y, Estabrooks SK, Ye Z, Id RMB, Assimon VA, et al. Predicting protein targets for drug-like compounds using transcriptomics. 2018;1\u201324."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07308-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07308-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07308-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:16:14Z","timestamp":1781622974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07308-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7308"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07308-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is updated to correct the error in author name.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1397"}}